JP2008526950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526950A5 JP2008526950A5 JP2007550879A JP2007550879A JP2008526950A5 JP 2008526950 A5 JP2008526950 A5 JP 2008526950A5 JP 2007550879 A JP2007550879 A JP 2007550879A JP 2007550879 A JP2007550879 A JP 2007550879A JP 2008526950 A5 JP2008526950 A5 JP 2008526950A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- group
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 238000004519 manufacturing process Methods 0.000 claims 15
- 229920006395 saturated elastomer Polymers 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 239000001301 oxygen Substances 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000001589 carboacyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 210000000265 leukocyte Anatomy 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000016396 cytokine production Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 230000004968 inflammatory condition Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 108010002352 Interleukin-1 Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108010002616 Interleukin-5 Proteins 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 3
- 108090001007 Interleukin-8 Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 3
- 210000003714 granulocyte Anatomy 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000000770 proinflammatory effect Effects 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 241000238366 Cephalopoda Species 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010029379 Neutrophilia Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 206010062952 diffuse panbronchiolitis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000016366 nasal cavity polyp Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000003519 ventilatory effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64384105P | 2005-01-13 | 2005-01-13 | |
| US60/643,841 | 2005-01-13 | ||
| US71582805P | 2005-09-09 | 2005-09-09 | |
| US60/715,828 | 2005-09-09 | ||
| PCT/IB2006/001238 WO2006087644A2 (en) | 2005-01-13 | 2006-01-13 | Macrolides with anti-inflammatory activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526950A JP2008526950A (ja) | 2008-07-24 |
| JP2008526950A5 true JP2008526950A5 (enExample) | 2009-02-26 |
| JP5036558B2 JP5036558B2 (ja) | 2012-09-26 |
Family
ID=36916830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007550879A Expired - Fee Related JP5036558B2 (ja) | 2005-01-13 | 2006-01-13 | 抗炎症活性を有するマクロライド |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8080529B2 (enExample) |
| EP (1) | EP1851236B1 (enExample) |
| JP (1) | JP5036558B2 (enExample) |
| KR (1) | KR20070105993A (enExample) |
| CN (1) | CN101142225B (enExample) |
| AT (1) | ATE476438T1 (enExample) |
| AU (1) | AU2006215315B2 (enExample) |
| CA (1) | CA2594820A1 (enExample) |
| CY (1) | CY1110866T1 (enExample) |
| DE (1) | DE602006015919D1 (enExample) |
| DK (1) | DK1851236T3 (enExample) |
| HR (1) | HRP20100549T1 (enExample) |
| IL (1) | IL184438A (enExample) |
| NO (1) | NO20074162L (enExample) |
| PL (1) | PL1851236T3 (enExample) |
| PT (1) | PT1851236E (enExample) |
| RS (1) | RS51479B (enExample) |
| WO (1) | WO2006087644A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518799A (ja) * | 2008-04-23 | 2011-06-30 | グラクソ グループ リミテッド | ２’−ｏ，３’−ｎ−橋かけマクロライド |
| CN101423539B (zh) * | 2008-12-09 | 2011-04-27 | 山东大学 | 4″,11-二氨基甲酸酯阿奇霉素衍生物、制备方法及其药物组合物 |
| JP5437394B2 (ja) * | 2009-01-30 | 2014-03-12 | グラクソ グループ リミテッド | 抗炎症性マクロライド |
| WO2011018510A1 (en) | 2009-08-13 | 2011-02-17 | Basilea Pharmaceutica Ag | New macrolides and their use |
| WO2011131749A1 (en) | 2010-04-23 | 2011-10-27 | Glaxo Group Limited | New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases |
| EP4095146A1 (en) | 2013-04-04 | 2022-11-30 | President And Fellows Of Harvard College | Macrolides and methods of their preparation and use |
| EP2984087A1 (en) | 2013-04-10 | 2016-02-17 | Probiotic Pharmaceuticals APS | Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect |
| JP2017531663A (ja) * | 2014-10-08 | 2017-10-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | １４員ケトライドならびにそれらの調製および使用の方法 |
| WO2016154591A1 (en) | 2015-03-25 | 2016-09-29 | President And Fellows Of Harvard College | Macrolides with modified desosamine sugars and uses thereof |
| GB201520419D0 (en) | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
| US12390440B2 (en) * | 2020-03-12 | 2025-08-19 | Zoetis Services Llc | Immunomodulating trifluoromethyl-aminal azalides |
| WO2022128054A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammatory conditions of human skin (iv) |
| CN114858953B (zh) * | 2022-05-20 | 2023-11-21 | 大连工业大学 | 一种动物源食品中红霉素及降解产物的检测试剂盒及检测方法 |
| GB202404587D0 (en) | 2024-03-28 | 2024-05-15 | Epiendo Pharmaceuticals Ehf | Chemical forms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0126344A2 (en) * | 1983-05-20 | 1984-11-28 | Abbott Laboratories | Tripeptide esters of therapeutic agents |
| SI9011409A (en) * | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
| EP0895999A1 (en) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
| HRP980189B1 (en) | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
| CN100577681C (zh) * | 2002-07-08 | 2010-01-06 | 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 | 用于治疗炎性疾病和病症的新化合物、组合物和方法 |
| GB0310986D0 (en) * | 2003-05-13 | 2003-06-18 | Glaxo Group Ltd | Novel compounds |
| ES2317527T3 (es) | 2005-01-13 | 2009-04-16 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Decladinosil-macrolidos que presentan actividad anti-inflamatoria. |
| EP1836212B1 (en) | 2005-01-14 | 2011-09-07 | Glaxo Group Limited | Macrolide compounds containing biotin and photo-affinity group for macrolide target identification |
| JP5437394B2 (ja) | 2009-01-30 | 2014-03-12 | グラクソ グループ リミテッド | 抗炎症性マクロライド |
-
2006
- 2006-01-13 DE DE602006015919T patent/DE602006015919D1/de not_active Expired - Lifetime
- 2006-01-13 KR KR1020077018362A patent/KR20070105993A/ko not_active Ceased
- 2006-01-13 DK DK06727595.8T patent/DK1851236T3/da active
- 2006-01-13 PL PL06727595T patent/PL1851236T3/pl unknown
- 2006-01-13 JP JP2007550879A patent/JP5036558B2/ja not_active Expired - Fee Related
- 2006-01-13 WO PCT/IB2006/001238 patent/WO2006087644A2/en not_active Ceased
- 2006-01-13 RS RSP-2010/0452A patent/RS51479B/sr unknown
- 2006-01-13 US US11/813,873 patent/US8080529B2/en not_active Expired - Fee Related
- 2006-01-13 HR HR20100549T patent/HRP20100549T1/hr unknown
- 2006-01-13 AT AT06727595T patent/ATE476438T1/de active
- 2006-01-13 EP EP06727595A patent/EP1851236B1/en not_active Expired - Lifetime
- 2006-01-13 CA CA002594820A patent/CA2594820A1/en not_active Abandoned
- 2006-01-13 AU AU2006215315A patent/AU2006215315B2/en not_active Ceased
- 2006-01-13 CN CN2006800081835A patent/CN101142225B/zh not_active Expired - Fee Related
- 2006-01-13 PT PT06727595T patent/PT1851236E/pt unknown
-
2007
- 2007-07-05 IL IL184438A patent/IL184438A/en not_active IP Right Cessation
- 2007-08-13 NO NO20074162A patent/NO20074162L/no not_active Application Discontinuation
-
2010
- 2010-10-26 CY CY20101100961T patent/CY1110866T1/el unknown
-
2011
- 2011-11-15 US US13/296,352 patent/US20120058963A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023106403A5 (enExample) | ||
| JP7368419B2 (ja) | アルドース還元酵素阻害剤およびその使用方法 | |
| JP2009507909A5 (enExample) | ||
| US7709664B2 (en) | Coumarin derivatives useful as TNFα inhibitors | |
| JP2004529140A5 (enExample) | ||
| JP2019510787A5 (enExample) | ||
| JP2005519932A5 (enExample) | ||
| JP2005528443A5 (enExample) | ||
| CN1128789C (zh) | 苯并环庚并噻吩化合物 | |
| JP2005509642A5 (enExample) | ||
| JP2010013466A (ja) | １−（２−ヒドロキシメチル）−１，３−オキサチオラン−５−イル）−シトシンのｂ型肝炎治療への使用 | |
| CN1610680A (zh) | 莨菪品酯的制备方法 | |
| JP2008526999A5 (enExample) | ||
| JP2022533958A5 (enExample) | ||
| JP2009526831A5 (enExample) | ||
| RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
| JP2007522142A5 (enExample) | ||
| CN119490510A (zh) | Pde4b抑制剂及其用途 | |
| KR20130108985A (ko) | (6，7-디히드로-2-니트로-5ｈ-이미다졸[2,1-ｂ][1,3]옥사진-6-일)아미드 화합물, 그의 제조방법 및 용도 | |
| JP2005507390A5 (enExample) | ||
| HRP20100549T1 (hr) | Makrolidi s protuupalnom aktivnošću | |
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| AU683287B2 (en) | Novel 9-N-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines | |
| CA2483345A1 (en) | Imidazolinylmethyl aralkylsulfonamides | |
| JP2004536079A5 (enExample) |